Browse News
Filter News
Found 270 articles
-
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
3/22/2024
Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19.
-
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
3/22/2024
Invivyd, Inc. announced that PEMGARDA™, formerly VYD222, a half-life extended monoclonal antibody, has received emergency use authorization from the U.S. FDA for the pre-exposure prophylaxis of COVID-19 in adults and adolescents who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination.
-
Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
2/28/2024
Ginkgo Bioworks announced the creation of the Ginkgo Technology Network - a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
-
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
2/23/2024
Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with EGPA were published in the New England Journal of Medicine today,1 as the first head-to-head trial of biologics in patients with EGPA,2 and the first to demonstrate that more than half of patients achieved remission with eosinophil-targeting biologic therapies.
-
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
2/12/2024
Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).
-
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
1/8/2024
Xilio Therapeutics, Inc. (Nasdaq: XLO) today highlighted recent advances across its clinical pipeline and reported encouraging preliminary safety data from the first three dose levels in the ongoing Phase 1 trial evaluating XTX301, a tumor-activated IL-12, in patients with advanced solid tumors.
-
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
12/7/2023
Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced the initiation of enrollment for its Phase 1 clinical trial of XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab and reported updated monotherapy data from its ongoing Phase 1 clinical trial evaluating XTX101 in late-line patients with advanced and immuno-oncology (IO) refractory solid tumors.
-
MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
11/21/2023
MIRA Pharmaceuticals, Inc. today revealed groundbreaking insights into the cognitively enhancing effects of MIRA1a in normal mice during a presentation at the University of Louisville's Christine Lee Brown Envirome Institute's Grand Rounds.
-
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
11/21/2023
MIRA Pharmaceuticals, Inc. today announced it will host a shareholder update call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time.
-
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
11/20/2023
MIRA Pharmaceuticals, Inc., an innovative pre-clinical-stage pharmaceutical company, announced a partnership with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder.
-
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
11/14/2023
Evoke Pharma, Inc. announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI.
-
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
11/14/2023
Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.
-
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
11/9/2023
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2023.
-
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 2023 financial results and provided a business update.
-
Rampart Health Bursts Out of Stealth Mode to Report 77% Disease Control in Metastatic Cancer from First-in-Human Phase 2 Trial ("Abscopal 5001") of Multiplex Intra-tumoral Immunotherapy (MITI)
11/6/2023
Rampart Health announced positive preliminary results of the first-ever prospective trial of a novel treatment delivered directly into cancer at the Society of Immunotherapy in Cancer Annual Meeting.
-
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
11/3/2023
Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced initial safety, pharmacokinetic (PK), pharmacodynamic (PD) and anti-tumor activity data from its ongoing Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in late line patients with advanced solid tumors.
-
Mayo Clinic and Oxford Nanopore announce collaboration to advance precision medicine for cancer and genetic disorders
10/19/2023
Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care.
-
Theralase(R) Files US Patent for Enhanced Immunotherapy
10/5/2023
Theralase Technologies Inc. is focused on the safe and effective destruction of various cancers, bacteria and viruses, when light or radiation activated.
-
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
9/11/2023
Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppressive therapy.
-
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion
9/7/2023
Kodiak Sciences Inc. announced top-line, one-year results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion.